




Correction to: Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively

Samuel R. Chamberlain^{1,2,3,4} · David S. Baldwin^{1,2,5,6} 

Published online: 25 November 2021
© Springer Nature Switzerland AG 2021

Correction to: CNS Drugs (2021) 35:703–716
<https://doi.org/10.1007/s40263-021-00832-x>

In the original publication, page 705, column 1—the sentence at the end of the first paragraph that read:

“The actuarial risk of severe cerebrovascular events (including deaths) due to hypertensive reactions is low, variously estimated as lying between 0.0014 and 0.007% [24–26] (i.e. 140–700 events per 100,000 patients treated).”
should read

“The actuarial risk of severe cerebrovascular events (including deaths) due to hypertensive reactions is low, variously estimated as lying between 0.00143 and 0.007% [24–26] (i.e. 1.43–7.0 events per 100,000 patients treated).”

The original article can be found online at <https://doi.org/10.1007/s40263-021-00832-x>.

✉ David S. Baldwin
d.s.baldwin@soton.ac.uk

¹ Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK

² Southern Health NHS Foundation Trust, Southampton, UK

³ Department of Psychiatry, University of Cambridge, Cambridge, UK

⁴ Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK

⁵ University Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa

⁶ University Department of Psychiatry, University of Southampton, College Keep, 4-12 Terminus Terrace, Southampton SO14 3DT, UK